KUNTUO is IQVIA's China-focused clinical research subsidiary, operating as a full-service CRO for domestic and international pharma companies. The tech stack reveals a heavy emphasis on simulation and design tools (Zemax, HFSS, Ansys, Solidworks, MATLAB) alongside oncology and medical device projects—unusual for a pure services business, suggesting deep technical involvement in trial design and protocol optimization rather than pure project administration. Active hiring is concentrated in research roles with mid-level seniority, but velocity is decelerating, indicating either market headwinds or achieved capacity targets.
KUNTUO has operated as a wholly-owned IQVIA subsidiary since 2011, providing end-to-end clinical trial services across oncology, psychiatry, cardiovascular, and medical device sectors in China. Core service lines include project management, clinical monitoring, data management, statistical analysis, site management, and early-stage regulatory strategy. The company serves both multinational pharma and domestic life sciences firms navigating China's regulatory environment. With 501–1,000 employees based in Beijing, the organization manages multiple concurrent trial sites while handling NDA/IND submissions and ensuring GCP compliance.
KUNTUO provides full-process clinical trial services in China: project management, clinical monitoring, data management, statistics, site management, regulatory interpretation, and medical support for pharma, medical device, and IVD companies.
Yes. Research roles make up 55 of 86 active positions, with mid-level (32) and junior (28) seniority dominating. However, hiring velocity is decelerating.
Oncology, psychiatry, cardiovascular diseases, medical devices, and in vitro diagnostic reagents. Active projects include cancer studies, RDC drug trials, and oncology clinical trials.
Other companies in the same industry, closest in size